<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url>
    <loc>https://peptidesciencedaily.com/news/fda-advisory-committee-503a-peptides-july-2026</loc>
    <news:news>
      <news:publication>
        <news:name>Peptide Science Daily</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-01T09:00:00Z</news:publication_date>
      <news:title>FDA Advisory Committee to Weigh Compounding of BPC-157 and Other Research Peptides</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://peptidesciencedaily.com/research/retatrutide-phase-2-triple-agonist-obesity-trial</loc>
    <news:news>
      <news:publication>
        <news:name>Peptide Science Daily</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-01T09:00:00Z</news:publication_date>
      <news:title>Retatrutide Phase 2: A Triple-Agonist Peptide and 24% Average Weight Loss at 48 Weeks</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://peptidesciencedaily.com/news/fda-scientists-question-peptides-rfk-ahead-of-panel-july-2026</loc>
    <news:news>
      <news:publication>
        <news:name>Peptide Science Daily</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-07-01T09:00:00Z</news:publication_date>
      <news:title>FDA Scientists Question Evidence for Peptides Backed by RFK Jr. Ahead of Advisory Panel</news:title>
    </news:news>
  </url>
</urlset>
